Status:

TERMINATED

Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer

Lead Sponsor:

Cell Genesys

Conditions:

Prostate Cancer

Eligibility:

MALE

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

V-0039 is a Phase 1/2 dose escalation trial of CG7870 in combination with Docetaxel in metastatic hormone-refractory patients who have not received chemotherapy. All patients will receive docetaxel. ...

Eligibility Criteria

Inclusion

  • Histologically confirmed adenocarcinoma of the prostate
  • Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy (after discontinuation of anti-androgen therapy)
  • Detectable metastases by bone scan, and/or CT scan, and/or MRI, and/or CXR
  • ECOG performance status 0-1

Exclusion

  • Transitional cell, small cell, neuroendocrine, or squamous cell prostate cancer
  • History of deep vein thrombosis or pulmonary embolus
  • Patients taking anticoagulants (such as coumadin or Heparin). The use of aspirin while on study is acceptable.
  • History of a bleeding disorder or recent clinically significant bleeding
  • Seropositive for HIV
  • History of Hepatitis B, Hepatitis C, or chronic liver disease
  • Prior gene therapy or immunotherapy
  • Prior chemotherapy for prostate cancer
  • Radiation therapy within 4 weeks of the first treatment.
  • History of myocardial infarction within 6 months of the first treatment
  • History of cerebrovascular accident
  • History of previous malignancy, except for the following: adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, adequately treated Stage I or II cancer currently in complete remission, or any other cancer that has been in complete remission for at least 5 years
  • Evidence of active prostatitis
  • Known hypersensitivity to docetaxel or to other drugs formulated with polysorbate 80

Key Trial Info

Start Date :

August 1 2004

Trial Type :

INTERVENTIONAL

End Date :

Estimated Enrollment :

69 Patients enrolled

Trial Details

Trial ID

NCT00103428

Start Date

August 1 2004

Last Update

February 2 2006

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Mary Crowley Medical Research Center

Dallas, Texas, United States, 75246